SEC Form 4	
FORM 4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

1. Name and Address of Reporting Person [*] <u>Templeman Thomas</u>				2. Issuer Name and Ticker or Trading Symbol <u>Centessa Pharmaceuticals plc</u> [CNTA]								5. Relationship of Repo (Check all applicable) Director X Officer (give ti			10% Owner le Other (specify			
(Last)(First)(Middle)C/O CENTESSA PHARMACEUTICALS PLC3RD FL., 1 ASHLEY RD, ALTRINCHAM				3. Date of Earliest Transaction (Month/Day/Year) 06/02/2021								below) Chie	ef Techr	nology	below) Officer			
(Street) CHESHIRE X0 WA14 2DT					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Indiv X	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(State) (Zip)																	
			Table I - Non-	Deriva	ative	Securitie	es Ao	cquired	, Dis	posed	of, or Be	nefi	cially O	wned				
1. Title of Security (Instr. 3) 2. Trans. Date (Month/t				Date		2A. Deemed Execution Date if any (Month/Day/Yea		Code (Instr.		4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4			5. Amount Securities Beneficially Following Reported	rities ficially Owned wing		Direct Indirect tr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
						Code	v	Amoun	t (A) ((D)	or	Price	Transaction (Instr. 3 and						
Ordinary Shares ⁽¹⁾ 06/02)2/2021		Р	Γ	25	i0 A		\$20	250			D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable ar Expiration Date (Month/Day/Year)			7. Title and Amour Securities Underly Derivative Security 3 and 4)		rlying	8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securiti Benefici Owned Followir Reporte Transac	ve es ially ng d	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisa		xpiration ate	Title	Nu	nount or mber of ares		(Instr. 4)			
Share Option (right to buy)	\$9.42 ⁽²⁾	04/20/2021		A ⁽³⁾		500,338 ⁽²⁾		(4)	0	4/20/2031	Ordinary Shares ⁽¹⁾⁽⁵⁾	50	0,338 ⁽²⁾	\$0.00	500,33	38 ⁽²⁾	D	

Explanation of Responses:

Instruction 1(b)

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital ("Share Split"). This amount has been adjusted to give effect to the Share Split.

3. This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3

4. 25% of the shares subject to such option shall vest and become exercisable on May 17, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.

5. Represented A Ordinary Shares that were redesignated as Ordinary Shares immediately prior to the closing of the initial public offering.

Remarks:

/s/ Marella Thorell, attorney-in-06/04/2021 <u>fact</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.